Summary of eosinophil counts at baseline for the ECLIPSE study
| Baseline eosinophils, cells/μL | COPD: ICS use at baseline (n=1499) | COPD: no ICS use at baseline (n=594) | Non-COPD controls (n=564) |
|---|---|---|---|
| Eosinophil count, median (IQR) | 180 (110 to 290) | 190 (120 to 270) | 150 (90 to 230) |
| Eosinophil count ≥150 cells/μL, n (%) | 918 (61) | 374 (63) | 290 (51) |
| Eosinophil count ≥300 cells/μL, n (%) | 347 (23) | 121 (20) | 73 (13) |
COPD, chronic obstructive pulmonary disease; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End points; ICS, inhaled corticosteroids; IQR, interquartile range.